Department of Psychiatry, Yale University, New Haven, CT, USA.
Pharmacol Biochem Behav. 2012 Nov;103(1):95-101. doi: 10.1016/j.pbb.2012.08.009.
Prior work by our group has shown the feasibility, safety, and validity of a multi-day, multi-dose paradigm of self-regulated cocaine administration in humans. The current work sought to consolidate these methods in a single-day design focused on reducing logistical complexity, decreasing research burden to human subjects, and increasing suitability for medication development designs.
Eleven experienced cocaine users participated in a 6-hour, single-day design, consisting of one safety/eligibility and three experimental cocaine periods (during which subjects were allowed to self-administer 8, 16, and 32 mg/70 kg cocaine doses under a fixed-ratio 1:5 minute timeout schedule). Changes in cocaine-induced cardiovascular response, self-administration behavior, and subjective effects were assessed.
Procedures were well tolerated by participants, and no significant adverse events were noted. Significant (p < 0.05), changes in measures of cocaine self-administration (e.g., responses, infusions, interinfusion intervals, consumption, and plasma levels), cardiovascular response (HR), and subjective effects (“high”) were observed. In contrast, cocaine-induced increases in other vital signs (e.g., SBP, DBP) and subjective effect measures (e.g., paranoia) did not differ between doses.
These data support the safety, tolerability and validity of our single-day design. Depending on the application, such methods may afford advantages for assessing the self-regulation of cocaine administration behavior in humans (e.g., including medication development designs).
我们小组之前的工作已经证明了在人类中进行多天、多剂量自我调节可卡因给药范式的可行性、安全性和有效性。目前的工作旨在将这些方法整合到一个单日设计中,重点是降低物流复杂性,减少对人类受试者的研究负担,并提高适合药物开发设计的能力。
11 名有经验的可卡因使用者参与了一个 6 小时的单日设计,包括一个安全性/合格性和三个实验可卡因期(在此期间,受试者根据固定比例 1:5 分钟超时时间表允许自我给予 8、16 和 32 毫克/70 公斤可卡因剂量)。评估了可卡因引起的心血管反应、自我给药行为和主观效应的变化。
参与者对程序的耐受性良好,没有观察到明显的不良事件。可卡因自我给药(例如,反应、输注、输注间隔、消耗和血浆水平)、心血管反应(HR)和主观效应(“高”)的测量值发生了显著变化(p < 0.05)。相比之下,剂量之间其他生命体征(例如,SBP、DBP)和主观效应测量值(例如,偏执)的可卡因诱导增加没有差异。
这些数据支持我们的单日设计的安全性、耐受性和有效性。根据应用的不同,这些方法可能在评估人类可卡因给药行为的自我调节方面具有优势(例如,包括药物开发设计)。